Plain-English translation of NCT05870475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether works better when combined with compared to alone. The study is for people with polycythemia vera — a blood condition where the body makes too many red blood cells — who couldn't tolerate or didn't respond well to their previous treatment (hydroxyurea). You would be randomly assigned to receive either the combination of both medications or just the single medication.
Many patients with polycythemia vera can't tolerate or don't respond adequately to standard treatment, leaving them with limited options. This trial is testing whether adding a second medication to the standard treatment might help these patients better control their condition and improve their symptoms.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to one of two groups: one group receives a weekly injection of one medication plus twice-daily pills of another medication, while the other group receives only the weekly injection. You'll be monitored for at least 12 weeks to see how well the treatment works. If the single medication isn't working well enough after 12 weeks, you may be able to switch to the combination treatment, and if you can't tolerate the combination, you can switch back to the single medication.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~94 participants
Started
June 2023
Primary completion
March 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lei Zhang, MD
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.